COVID-19 vaccine development (Moderna)

URI: https://gptkb.org/entity/COVID-19_vaccine_development_(Moderna)

GPTKB entity

Statements (50)

Predicate	Object
gptkbp:instanceOf	COVID-19 vaccine development project
gptkbp:age	18 and older 12 and older (in some countries)
gptkbp:approvalYear	August 23, 2021
gptkbp:associatedWith	gptkb:Pfizer–BioNTech_COVID-19_vaccine gptkb:AstraZeneca_COVID-19_vaccine gptkb:Johnson_&_Johnson_COVID-19_vaccine
gptkbp:boosterRecommended	Yes
gptkbp:brand	gptkb:Spikevax
gptkbp:clinicalTrialPhase	Phase 1 Phase 2 Phase 3
gptkbp:collaboratesWith	gptkb:National_Institute_of_Allergy_and_Infectious_Diseases
gptkbp:countryOfOrigin	gptkb:United_States
gptkbp:developer	gptkb:Moderna,_Inc.
gptkbp:distribution	global
gptkbp:dosageSchedule	Two doses, 28 days apart
gptkbp:effect	~94% (original clinical trials)
gptkbp:emergencyUseAuthorizationDate	December 18, 2020
gptkbp:firstHumanTrialDate	gptkb:March_16,_2020
gptkbp:fundedBy	gptkb:U.S._government
https://www.w3.org/2000/01/rdf-schema#label	COVID-19 vaccine development (Moderna)
gptkbp:notablePerson	gptkb:Kizzmekia_Corbett gptkb:Noubar_Afeyan gptkb:Stéphane_Bancel gptkb:Barney_Graham gptkb:Tal_Zaks
gptkbp:patent	gptkb:Moderna,_Inc.
gptkbp:platform	gptkb:gene
gptkbp:publishedIn	gptkb:New_England_Journal_of_Medicine gptkb:The_Lancet
gptkbp:regulates	gptkb:World_Health_Organization gptkb:European_Medicines_Agency gptkb:Health_Canada gptkb:Therapeutic_Goods_Administration_(Australia) gptkb:MHRA_(UK)
gptkbp:sideEffect	fever fatigue headache muscle pain chills injection site pain
gptkbp:storage	-20°C
gptkbp:target	gptkb:COVID-19
gptkbp:vaccineType	gptkb:mRNA-1273 vaccine
gptkbp:variantBoosterDeveloped	Yes
gptkbp:WHOEmergencyUseListing	April 30, 2021
gptkbp:bfsParent	gptkb:Noubar_Afeyan
gptkbp:bfsLayer	5